

More evidence for a Gi-regulated ras exchanger.

T W Sturgill

J Clin Invest. 1994;[94](#)(2):471-471. <https://doi.org/10.1172/JCI117357>.

Editorial

Find the latest version:

<https://jci.me/117357/pdf>



The MAP kinase pathway is a signal transduction module that is activated in many cell types by many agonists. Two apparently redundant MAP kinase isoforms p42^{mapk}/ERK 2 and p44^{mapk}/ERK1 are effectors in the pathway, targeting a number of substrates of regulatory significance prominently including transcription factors, two protein kinases, and cytoplasmic phospholipase A₂ (1). MAP kinase is regulated by dual tyrosine and threonine phosphorylation in a conserved TEY motif catalyzed by remarkably specific MAP kinase kinases (MKKs) or MEKs (see reference 2 and references therein). A family of mammalian protein kinases related to MAP kinase exists, all regulated by closely spaced tyrosine and threonine phosphorylations. The MAP kinase kinase/MAP kinase pairs are likely not to cross-activate. MEK 1 and MEK 2 do not activate the other MAP kinases examined.

In this issue of *The Journal*, Worthen and co-workers studied the mechanism of activation of the MAP kinase pathway by f-Met-Leu-Phe (FMLP). As a result of these studies, the authors have provided additional important evidence for a G_i regulated Ras exchanger. MEKs are activated in vitro by at least two protein kinases that are widely expressed in mammalian cells, the proto-oncogene Raf and the MEK kinase cloned and characterized in Dr. G. Johnson's laboratory (3). Lange-Carter and co-workers hypothesized that MEK kinase might account for MAP kinase activation by G proteins (3).

Surprisingly, several papers (4–5) including a previous paper from the Johnson lab (6) and now including the Worthen paper (6) have demonstrated that agonists that activate MAP

kinase through a G_i pathway do so via a mechanism dependent on p21 Ras. Lysophosphatidic acid (4), adrenergic agonists via alpha 2A receptors (5), carbachol via muscarinic m2 receptors (6), and FMLP (7) have all now been shown to activate Ras and MAP kinase. In each case, GTP loading of Ras and MAP kinase activation are blocked by pertussis toxin which is not known to ADP ribosylate Ras. Ras GTP loading is required for activation of Raf. Thus several G proteins that were good candidates for participation in a Ras-independent pathway, possibly involving MEK kinase, appear instead to participate in a Ras/Raf pathway. MEK kinase is still looking for an activator. Identification of the mechanism of G_i -stimulated Ras activation promises to be an exciting arena for friendly competition among the signal transduction laboratories.

Thomas W. Sturgill, M.D., Ph.D.
Howard Hughes Medical Institute
University of Virginia Health Sciences Center

References

1. Davis, R. J. 1993. The mitogen-activated protein kinase signal transduction pathway. *J. Biol. Chem.* 268:14553–14556.
2. Wu, J., J. K. Harrison, P. Dent, K. R. Lynch, M. J. Weber, and T. W. Sturgill. 1993. Identification and characterization of a new mammalian mitogen-activated protein kinase kinase, MKK2. *Mol. Cell. Biol.* 13:4539–4548.
3. Lange-Carter, C. A., C. M. Pleiman, A. M. Gardner, K. J. Blumer, and G. L. Johnson. 1993. A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf. *Science (Wash. DC)*. 260:315–319.
4. Howe, L. R., and C. J. Marshall. 1993. Lysophosphatidic acid stimulates mitogen-activated protein kinase activation via a G-protein-coupled pathway requiring p21ras and p74raf-1. *J. Biol. Chem.* 268:20717–20720.
5. Alblas, J., E. J. van Corven, P. L. Hordijk, G. Milligan, and W. H. Mooleenaar. 1993. G_i -mediated activation of the p21ras-mitogen-activated protein kinase pathway by alpha 2-adrenergic receptors in fibroblasts. *J. Biol. Chem.* 268:22235–22238.
6. Winitz, S., M. Russell, N. X. Qian, A. Gardner, L. Dwyer, and G. L. Johnson. 1993. Involvement of Ras and Raf in the G_i -coupled acetylcholine muscarinic m₂ receptor activation of mitogen-activated protein (MAP) kinase kinase and MAP kinase. *J. Biol. Chem.* 268:19196–19199.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/94/08/0471/01 \$2.00

Volume 94, August 1994, 471